Heart Test Laboratories, Inc. (NASDAQ:HSCS) Short Interest Update

Heart Test Laboratories, Inc. (NASDAQ:HSCS) was the target of a significant decrease in short interest in January. As of January 31st, there was short interest totalling 33,300 shares, a decrease of 13.5% from the January 15th total of 38,500 shares. Based on an average daily volume of 35,000 shares, the days-to-cover ratio is currently 1.0 days. Approximately 4.1% of the shares of the company are short sold.

Wall Street Analysts Forecast Growth

Separately, Maxim Group reiterated a “buy” rating and set a $12.00 price objective on shares of Heart Test Laboratories in a research note on Wednesday, December 18th.

Heart Test Laboratories Stock Performance

Heart Test Laboratories stock opened at $3.98 on Tuesday. Heart Test Laboratories has a 52-week low of $2.36 and a 52-week high of $18.50. The company has a debt-to-equity ratio of 0.01, a current ratio of 1.72 and a quick ratio of 1.52. The stock has a fifty day moving average price of $3.62 and a two-hundred day moving average price of $3.44. The firm has a market capitalization of $3.90 million, a P/E ratio of -0.50 and a beta of 2.88.

Heart Test Laboratories (NASDAQ:HSCS) last issued its quarterly earnings results on Monday, December 16th. The company reported ($2.27) EPS for the quarter, topping analysts’ consensus estimates of ($2.30) by $0.03. During the same period in the prior year, the business earned ($15.92) EPS. As a group, analysts anticipate that Heart Test Laboratories will post -10.01 EPS for the current fiscal year.

Heart Test Laboratories Company Profile

Heart Test Laboratories, Inc, a medical technology company, provides cardiovascular diagnostic devices. The company offers MyoVista wavECG, a resting 12-lead electrocardiograph (ECG) to provide diagnostic information related to cardiac dysfunction, as well as conventional ECG information. It serves clinics, doctor's offices, urgent care centers, and hospitals.